Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedRationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisPolycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementManagement of polycythaemia vera: a critical review of current data.The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteriaClinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaFrom leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Advances and challenges in the management of essential thrombocythemia.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients.European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.From anemia to polycythemia in 4 weeks.Straightforward identification of masked polycythemia vera based on proposed revision of World Health Organization diagnostic criteria for BCR-ABL1-negative myeloproliferative neoplasms.Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms.Diagnostic impact of the 2016 revised who criteria for polycythemia vera.The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria.SOHO State-of-the-Art Update and Next Questions: MPN.The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
P2860
Q26738514-86D20137-22C7-44D7-9FB1-35FEFE38D272Q26772881-20516196-4578-419B-91D7-FEE24B377A73Q26851894-880FD2F0-6C19-4F57-9F94-6C01D667DFB9Q31009757-38CA1B2E-88D2-4880-A025-AA257086ACBDQ33359793-F168B973-1757-4142-9DAB-8DDE2DB2698BQ36874807-2DACE807-2E16-468F-B8A3-32915537EE56Q37555790-AF9D4BFA-74B2-4CD2-A1B5-E624528475A8Q37679175-6A8C527A-436B-4F27-A94C-E8E2B1B85F0BQ38542093-9071D09D-3F07-4009-BA12-7BD8751273D7Q38613880-2189220B-5C0D-4686-9FD4-E3B7E450DB03Q38631064-F671D9A8-7D14-4957-A846-307081827444Q38689790-B08338E9-C26E-4161-9288-E4072A55FEC0Q38816384-8F52FF4B-8113-49AE-B638-00770F2DEBA1Q38826302-35F0C572-103C-4244-9A71-53F2A13E35E7Q41599861-A265B3E4-41E7-4342-809C-74E134AAC3BAQ43243282-0DA301F3-B706-4581-A555-445FB198D53EQ47829592-F602A427-23C9-4CFB-A58C-53FDB7D84710Q48238457-7A5DDEC1-F31B-4191-A9CB-EAD042A53A11Q48321438-F5AA0132-710B-42EA-A771-9B2C45333BEDQ49580473-3A3A6D1F-512D-4F84-A80C-9C7CECF2A146Q49633536-0C199880-BA85-4516-9E0B-DBA987DD56B4Q50449411-FFFACA22-CE5C-4DB3-8693-255B2EF47DADQ54329508-563B18C1-CAC1-49A2-AB43-253B50A3A87C
P2860
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Discriminating between essenti ...... vera in JAK2 mutated patients.
@en
Discriminating between essenti ...... vera in JAK2 mutated patients.
@nl
type
label
Discriminating between essenti ...... vera in JAK2 mutated patients.
@en
Discriminating between essenti ...... vera in JAK2 mutated patients.
@nl
prefLabel
Discriminating between essenti ...... vera in JAK2 mutated patients.
@en
Discriminating between essenti ...... vera in JAK2 mutated patients.
@nl
P2093
P2860
P356
P1476
Discriminating between essenti ...... vera in JAK2 mutated patients.
@en
P2093
Alessandra Carobbio
Alessandro M Vannucchi
Alessandro Rambaldi
Jürgen Thiele
Tiziano Barbui
P2860
P304
P356
10.1002/AJH.23694
P577
2014-03-03T00:00:00Z